- Home
- BILL vs MRUS Comparison
BILL vs MRUS Comparison
Compare BILL & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BILL
- MRUS
- Stock Information
- Founded
- BILL 2006
- MRUS 2003
- Country
- BILL United States
- MRUS Netherlands
- Employees
- BILL N/A
- MRUS N/A
- Industry
- BILL EDP Services
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- BILL Technology
- MRUS Health Care
- Exchange
- BILL Nasdaq
- MRUS Nasdaq
- Market Cap
- BILL 4.6B
- MRUS 4.1B
- IPO Year
- BILL 2019
- MRUS 2016
- Fundamental
- Price
- BILL $48.12
- MRUS $53.82
- Analyst Decision
- BILL Buy
- MRUS Strong Buy
- Analyst Count
- BILL 21
- MRUS 13
- Target Price
- BILL $62.89
- MRUS $88.54
- AVG Volume (30 Days)
- BILL 2.3M
- MRUS 839.8K
- Earning Date
- BILL 08-21-2025
- MRUS 07-31-2025
- Dividend Yield
- BILL N/A
- MRUS N/A
- EPS Growth
- BILL N/A
- MRUS N/A
- EPS
- BILL N/A
- MRUS N/A
- Revenue
- BILL $1,422,885,000.00
- MRUS $54,732,000.00
- Revenue This Year
- BILL $15.18
- MRUS $75.57
- Revenue Next Year
- BILL $12.31
- MRUS $31.84
- P/E Ratio
- BILL $129.13
- MRUS N/A
- Revenue Growth
- BILL 14.52
- MRUS 42.77
- 52 Week Low
- BILL $36.55
- MRUS $33.19
- 52 Week High
- BILL $100.19
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- BILL 62.34
- MRUS 55.07
- Support Level
- BILL $45.06
- MRUS $52.25
- Resistance Level
- BILL $47.00
- MRUS $54.18
- Average True Range (ATR)
- BILL 1.28
- MRUS 1.58
- MACD
- BILL 0.41
- MRUS -0.45
- Stochastic Oscillator
- BILL 96.03
- MRUS 47.48
About BILL BILL Holdings Inc.
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.